Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

An oncologist is managing a 59-year-old male with metastatic melanoma who recently completed his third cycle of pembrolizumab. The patient is admitted to the medical ward reporting 8 to 10 watery bowel movements daily, accompanied by severe abdominal cramping and trace hematochezia over the past two days. Vital signs are stable. He is clinically suspected of having severe (Grade 3) immune-mediated colitis. Arrange the following steps in the standard sequence for the diagnostic workup, therapeutic intervention, and longitudinal monitoring of this patient's condition.

  1. 1Perform comprehensive stool studies to rule out enteric infections, including Clostridioides difficile.
  2. 2Suspend the immune checkpoint inhibitor and commence high-dose intravenous methylprednisolone.
  3. 3Reassess the clinical response after 48 to 72 hours of initial immunosuppressive therapy.
  4. 4Initiate a second-line biologic immunosuppressant (e.g., infliximab) if symptoms remain refractory.
  5. 5Execute a gradual corticosteroid taper over 4 to 6 weeks once symptoms improve to Grade 1 or baseline.

Answer

The correct sequence begins with ruling out infection, followed by initiating high-dose corticosteroids, evaluating response at 48 to 72 hours, escalating to a biologic if refractory, and finally completing a prolonged 4 to 6 week steroid taper upon improvement.
The correct management sequence for Grade 3 immune-mediated colitis strictly follows oncologic guidelines. Infection must first be ruled out to ensure immunosuppression is safe. Once excluded, the checkpoint inhibitor is held, and intravenous corticosteroids are given. A mandatory monitoring interval of 48 to 72 hours dictates the next step: if symptoms improve, a slow 4-6 week taper is initiated when symptoms reach Grade 1; if symptoms do not improve, the patient is deemed steroid-refractory, and a biologic such as infliximab must be administered.

Step-by-Step Solution

1
Rule out infectious causes of acute severe diarrhea.
Stool studies for enteric pathogens and C. difficile are collected.
Empiric high-dose immunosuppression can be fatal if the underlying cause is infectious rather than autoimmune.
2
Initiate first-line immunosuppressive therapy for Grade 3 colitis.
Pembrolizumab is held and IV methylprednisolone (1-2 mg/kg/day) is administered.
High-dose systemic corticosteroids are the standard first-line treatment for severe immune-related adverse events.
3
Monitor for therapeutic efficacy over a standardized interval.
The patient is closely observed and reassessed at 48 to 72 hours.
This specific time window determines whether the immune-related adverse event is steroid-responsive or steroid-refractory.
4
Provide rescue therapy if the initial intervention fails.
Infliximab or vedolizumab is added if diarrhea frequency and abdominal pain do not improve.
Steroid-refractory cases require additional biologic immunosuppression to halt mucosal damage and systemic inflammation.
5
De-escalate therapy safely once the condition stabilizes.
Corticosteroids are transitioned to oral formulations and tapered over 4 to 6 weeks.
Rapid withdrawal of steroids in immune-mediated toxicities highly risks a flare or rebound of the immune response.

Key Concept

Monitoring and evaluation of immune-related adverse events (irAEs) requires a protocolized approach: exclude infection, begin high-dose steroids, evaluate at 48-72 hours for steroid refractoriness, escalate to biologics if necessary, and execute a 4-6 week taper to prevent rebound.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic